Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif.

Chen X, Riley BT, de Veer SJ, Hoke DE, Van Haeften J, Leahy D, Swedberg JE, Brattsand M, Hartfield PJ, Buckle AM, Harris JM.

PLoS One. 2019 Jan 22;14(1):e0210842. doi: 10.1371/journal.pone.0210842. eCollection 2019.

2.

Kallikrein-related peptidase 7 overexpression in melanoma cells modulates cell adhesion leading to a malignant phenotype.

Haddada M, Draoui H, Deschamps L, Walker F, Delaunay T, Brattsand M, Magdolen V, Darmoul D.

Biol Chem. 2018 Sep 25;399(9):1099-1105. doi: 10.1515/hsz-2017-0339.

PMID:
29498930
3.

Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion.

Delaunay T, Deschamps L, Haddada M, Walker F, Soosaipillai A, Soualmia F, El Amri C, Diamandis EP, Brattsand M, Magdolen V, Darmoul D.

Mol Oncol. 2017 Oct;11(10):1330-1347. doi: 10.1002/1878-0261.12103. Epub 2017 Aug 11.

4.

High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.

Djusberg E, Jernberg E, Thysell E, Golovleva I, Lundberg P, Crnalic S, Widmark A, Bergh A, Brattsand M, Wikström P.

Prostate. 2017 May;77(6):625-638. doi: 10.1002/pros.23307. Epub 2017 Feb 1.

PMID:
28144969
5.

Missing factors in human skin equivalent models?

Brattsand M.

Br J Dermatol. 2017 Jan;176(1):11-12. doi: 10.1111/bjd.15108. No abstract available.

PMID:
28098372
6.

KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.

Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, Brattsand M, Beck IM, Sedlacek R.

PLoS Genet. 2017 Jan 17;13(1):e1006566. doi: 10.1371/journal.pgen.1006566. eCollection 2017 Jan.

7.

Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.

de Veer SJ, Furio L, Swedberg JE, Munro CA, Brattsand M, Clements JA, Hovnanian A, Harris JM.

J Invest Dermatol. 2017 Feb;137(2):430-439. doi: 10.1016/j.jid.2016.09.017. Epub 2016 Sep 30.

8.

Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.

de Veer SJ, Swedberg JE, Brattsand M, Clements JA, Harris JM.

Biol Chem. 2016 Dec 1;397(12):1237-1249. doi: 10.1515/hsz-2016-0112.

PMID:
26894578
9.

Engineered protease inhibitors based on sunflower trypsin inhibitor-1 (SFTI-1) provide insights into the role of sequence and conformation in Laskowski mechanism inhibition.

de Veer SJ, Swedberg JE, Akcan M, Rosengren KJ, Brattsand M, Craik DJ, Harris JM.

Biochem J. 2015 Jul 15;469(2):243-53. doi: 10.1042/BJ20150412. Epub 2015 May 18.

PMID:
25981970
10.

Over-expression of kallikrein related peptidases in palmoplantar pustulosis.

Kaneko T, Murakami M, Kishibe M, Brattsand M, Morhenn VB, Ishida-Yamamoto A, Iizuka H.

J Dermatol Sci. 2012 Jul;67(1):73-6. doi: 10.1016/j.jdermsci.2012.03.009. Epub 2012 Apr 5. No abstract available.

PMID:
22520926
11.

Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis.

Brännström K, Ohman A, von Pawel Rammingen U, Olofsson A, Brattsand M.

Biol Chem. 2012 Apr;393(5):369-77. doi: 10.1515/hsz-2011-0238.

PMID:
22505519
12.

SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor.

Brattsand M, Stefansson K, Hubiche T, Nilsson SK, Egelrud T.

J Invest Dermatol. 2009 Jul;129(7):1656-65. doi: 10.1038/jid.2008.448. Epub 2009 Feb 5.

13.

The Schistosoma mansoni protein Sm16/SmSLP/SmSPO-1 assembles into a nine-subunit oligomer with potential To inhibit Toll-like receptor signaling.

Brännström K, Sellin ME, Holmfeldt P, Brattsand M, Gullberg M.

Infect Immun. 2009 Mar;77(3):1144-54. doi: 10.1128/IAI.01126-08. Epub 2009 Jan 5.

14.

Kallikrein-related peptidases.

Lundwall A, Brattsand M.

Cell Mol Life Sci. 2008 Jul;65(13):2019-38. doi: 10.1007/s00018-008-8024-3. Review.

PMID:
18344018
15.

Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases.

Stefansson K, Brattsand M, Roosterman D, Kempkes C, Bocheva G, Steinhoff M, Egelrud T.

J Invest Dermatol. 2008 Jan;128(1):18-25. Epub 2007 Jul 12.

16.

LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.

Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, Wagberg F, Brattsand M, Hachem JP, Leonardsson G, Hovnanian A.

Mol Biol Cell. 2007 Sep;18(9):3607-19. Epub 2007 Jun 27.

17.

Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum.

Stefansson K, Brattsand M, Ny A, Glas B, Egelrud T.

Biol Chem. 2006 Jun;387(6):761-8.

PMID:
16800737
18.

Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome.

Hachem JP, Wagberg F, Schmuth M, Crumrine D, Lissens W, Jayakumar A, Houben E, Mauro TM, Leonardsson G, Brattsand M, Egelrud T, Roseeuw D, Clayman GL, Feingold KR, Williams ML, Elias PM.

J Invest Dermatol. 2006 Jul;126(7):1609-21. Epub 2006 Apr 6.

19.

hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6.

Egelrud T, Brattsand M, Kreutzmann P, Walden M, Vitzithum K, Marx UC, Forssmann WG, Mägert HJ.

Br J Dermatol. 2005 Dec;153(6):1200-3.

PMID:
16307658
20.

A proteolytic cascade of kallikreins in the stratum corneum.

Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T.

J Invest Dermatol. 2005 Jan;124(1):198-203.

21.

Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7.

Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, Egelrud T, Simon M, Serre G.

J Invest Dermatol. 2004 May;122(5):1235-44.

22.

Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.

Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA.

Clin Cancer Res. 2003 May;9(5):1710-20.

23.

Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process?

Ekholm IE, Brattsand M, Egelrud T.

J Invest Dermatol. 2000 Jan;114(1):56-63.

25.

Molecular cloning and tissue expression of the murine analog to human stratum corneum chymotryptic enzyme.

Bäckman A, Strandén P, Brattsand M, Hansson L, Egelrud T.

J Invest Dermatol. 1999 Aug;113(2):152-5.

26.

Expression of stratum corneum chymotryptic enzyme in human sebaceous follicles.

Ekholm E, Sondell B, Strandén P, Brattsand M, Egelrud T.

Acta Derm Venereol. 1998 Sep;78(5):343-7.

PMID:
9779250

Supplemental Content

Loading ...
Support Center